# Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer

> **NCT03180437** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fuda Cancer Hospital, Guangzhou** · enrollment: 62 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **PROCEDURE:** IRE surgery
- **BIOLOGICAL:** IRE plus γδ T cells

## Key facts

- **NCT ID:** NCT03180437
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-15
- **Primary completion:** 2018-06-15
- **Final completion:** 2019-06-15
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03180437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03180437, "Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03180437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*